Skip to main content

1 Result(s)

within Won K. Kang Remove this filter

and

  1. Article

    Open Access

    Phase II study of sunitinib as second-line treatment for advanced gastric cancer

    Purpose. This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had re...

    Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku… in Investigational New Drugs (2011)

    Download PDF (210 KB) View Article